EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.

Saved in:
Bibliographic Details
Title: EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.
Authors: German B; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Morel KL; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide SA, Australia., Noel T; Cedars-Sinai Center for Bioinformatics and Functional Genomics, Los Angeles CA, USA., Boufaied N; Cancer Research Program, Research Institute of the McGill University Health Center, Montreal, QC, Canada., Burkhart DL; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA., Chen S; West China School of Public Health, West China Fourth Hospital, and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China., Dezem F; Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis TN, USA., Qui X; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA., Long HW; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA., DiFazio S; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA., Baca S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA., Shafi AA; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA., Freedman ML; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA., Sweeney CJ; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide SA, Australia., He HH; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada., Brown M; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA., Plummer JT; Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis TN, USA., Knott SRV; Cedars-Sinai Center for Bioinformatics and Functional Genomics, Los Angeles CA, USA.; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles CA, USA., Labbe DP; Cancer Research Program, Research Institute of the McGill University Health Center, Montreal, QC, Canada.; Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada., Ellis L; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Source: BioRxiv : the preprint server for biology [bioRxiv] 2025 Aug 11. Date of Electronic Publication: 2025 Aug 11.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2692-8205
DOI:10.1101/2025.08.07.669104